A coalition of patient and provider groups urges CMS to bar insurers from exempting drug manufacturer coupons from cost-sharing limits in the 2024 exchange rule, and stakeholders also urge HHS to consider the so-called “co-pay accumulators” discriminatory in its final rule on Section 1557 of the Affordable Care Act. Although Medicare bans the use of drug manufacturers’ co-pay coupons, they are allowed in the private market, including Affordable Care Act plans. Insurers say the coupons encourage high drug prices and...